Abstract

Multiple myeloma represents 1% of all cancers and 15% of hematologic malignancies ([1][1]). Despite improvements in outcomes for this disease over the past several decades, the 5-year survival rate is still only 50%. Kidney dysfunction is common in myeloma, and it is present in 40% of patients at

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call